Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Outlook Therapeutics (OTLK) over the last 7 years, with Q2 2025 value amounting to $20.4 million.

  • Outlook Therapeutics' Non-Current Debt changed N/A to $20.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $20.4 million, marking a year-over-year change of. This contributed to the annual value of $50285.0 for FY2019, which is 4894.25% down from last year.
  • As of Q2 2025, Outlook Therapeutics' Non-Current Debt stood at $20.4 million.
  • In the past 5 years, Outlook Therapeutics' Non-Current Debt ranged from a high of $21.0 million in Q1 2025 and a low of $20.4 million during Q2 2025